- Home
- OPI vs LPCN Comparison
OPI vs LPCN Comparison
Compare OPI & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPI
- LPCN
- Stock Information
- Founded
- OPI 2009
- LPCN 1997
- Country
- OPI United States
- LPCN United States
- Employees
- OPI N/A
- LPCN N/A
- Industry
- OPI Real Estate Investment Trusts
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- OPI Real Estate
- LPCN Health Care
- Exchange
- OPI Nasdaq
- LPCN Nasdaq
- Market Cap
- OPI 16.6M
- LPCN 16.1M
- IPO Year
- OPI 2009
- LPCN N/A
- Fundamental
- Price
- OPI $0.26
- LPCN $3.27
- Analyst Decision
- OPI
- LPCN Strong Buy
- Analyst Count
- OPI 0
- LPCN 2
- Target Price
- OPI N/A
- LPCN $9.00
- AVG Volume (30 Days)
- OPI 1.1M
- LPCN 31.0K
- Earning Date
- OPI 07-30-2025
- LPCN 08-07-2025
- Dividend Yield
- OPI 14.81%
- LPCN N/A
- EPS Growth
- OPI N/A
- LPCN N/A
- EPS
- OPI N/A
- LPCN N/A
- Revenue
- OPI $476,159,000.00
- LPCN $3,674,834.00
- Revenue This Year
- OPI N/A
- LPCN N/A
- Revenue Next Year
- OPI N/A
- LPCN N/A
- P/E Ratio
- OPI N/A
- LPCN N/A
- Revenue Growth
- OPI N/A
- LPCN N/A
- 52 Week Low
- OPI $0.18
- LPCN $2.68
- 52 Week High
- OPI $3.02
- LPCN $7.90
- Technical
- Relative Strength Index (RSI)
- OPI 52.40
- LPCN 52.27
- Support Level
- OPI $0.26
- LPCN $3.10
- Resistance Level
- OPI $0.34
- LPCN $3.39
- Average True Range (ATR)
- OPI 0.03
- LPCN 0.18
- MACD
- OPI 0.01
- LPCN 0.02
- Stochastic Oscillator
- OPI 46.23
- LPCN 39.77
About OPI Office Properties Income Trust of Beneficial Interest
Office Properties Income Trust is a United States-based real estate investment trust. Its property portfolio is mainly composed of single-tenant office buildings, as well as multitenant properties, which are leased to parties of high credit quality characteristics. Its major tenant is the U.S. government, followed by other smaller government entities and corporations. The company's properties are spread across the United States. The company has only one segment which is direct ownership of real estate properties.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.